Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2023;29(Suppl):S184-S195. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0318

View: 4394 Download: 190 Web of Science: 11 Crossref: 13

Snapshot

Personalized medicine in nonalcoholic fatty liver disease

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):935-938. Published online June 24, 2022

DOI: https://doi.org/10.3350/cmh.2022.0175

View: 4749 Download: 147 Web of Science: 7 Crossref: 6

Review

Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2020;26(4):461-475. Published online September 10, 2020

DOI: https://doi.org/10.3350/cmh.2020.0136

View: 8998 Download: 289 Web of Science: 40 Crossref: 40

2

Wilson Disease: an Update

Jeong Kee Seo

Clin Mol Hepatol. 2006;12(3):333-363. Published online January 1, 2000

View: 6905 Download: 241

Original Article

DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease

Amal Magdy, Hee-Jin Kim, Hanyong Go, Jun Min Lee, Hyun Ahm Sohn, Keeok Haam, Hyo-Jung Jung, Jong-Lyul Park, Taekyeong Yoo, Eun-Soo Kwon, Dong Hyeon Lee, Murim Choi, Keon Wook Kang, Won Kim, Mirang Kim

Received April 9, 2024 Accepted July 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0229 [Accepted]

View: 785 Download: 169

Review

Precision medicine and nucleotide-based therapeutics to treat MASH

Andrea Caddeo, Stefano Romeo

Received June 8, 2024 Accepted August 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0438 [Accepted]

View: 799 Download: 162 Crossref: 1

Correspondence

Correspondence on Letter regarding “A complement to epigenetics in MASLD”

Amal Magdy, Hee-Jin Kim, Won Kim, Mirang Kim

Received September 6, 2024 Accepted September 9, 2024

DOI: https://doi.org/10.3350/cmh.2024.0761 [Accepted]

View: 190 Download: 12

1 |

Viewed By 4999	MAFLD: How is it different from NAFLD?
Viewed By 4841	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4775	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4492	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4450	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 214	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 133	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 117	MAFLD: How is it different from NAFLD?
Cited By 95	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search